Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Relmada Therapeutics Inc is a biotechnology business based in the US. Relmada Therapeutics shares (RLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Relmada Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $18.99 |
|---|---|
| 52-week range | $15.74 - $35.35 |
| 50-day moving average | $21.11 |
| 200-day moving average | $22.10 |
| Wall St. target price | $59.71 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-6.99 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.99 from 2022-06-30
| 1 week (2022-06-24) | -3.36% |
|---|---|
| 1 month (2022-06-02) | 1.77% |
| 3 months (2022-03-31) | -29.64% |
| 6 months (2021-12-31) | -15.71% |
| 1 year (2021-07-02) | -41.77% |
|---|---|
| 2 years (2020-07-02) | -55.61% |
| 3 years (2019-07-02) | 955.00% |
| 5 years (2017-06-30) | 2,215.85% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -53.69% |
| Return on equity TTM | -95.03% |
| Profit margin | 0% |
| Book value | $7.16 |
| Market capitalisation | $589.6 million |
TTM: trailing 12 months
We're not expecting Relmada Therapeutics to pay a dividend over the next 12 months.
Relmada Therapeutics's shares were split on a 1:4 basis on 29 September 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Relmada Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Relmada Therapeutics shares which in turn could have impacted Relmada Therapeutics's share price.
Over the last 12 months, Relmada Therapeutics's shares have ranged in value from as little as $15.735 up to $35.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relmada Therapeutics's is 0.5422. This would suggest that Relmada Therapeutics's shares are less volatile than average (for this exchange).
Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.